GlassScriptPhysician profile
John Ellis
NPI 1417947417
$6,514.87
in general payments reported to CMS, 2019-2025
16 companies · $2,582 in 2025
The $2,582 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $937 · 2020: $672 · 2021: $804 · 2022: $919 · 2023: $221 · 2024: $380 · 2025: $2,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,918 · Travel and Lodging: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.46 |
| Travel and Lodging | $1,263.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,907.11 | 2024-2025 | Clariti Contact Lens, Myday Contact Lens |
| Alcon Vision LLC | $1,513.85 | 2019-2025 | Tryptyr, Hydrus Microstent, Eysuvis |
| Johnson & Johnson Vision Care, INC. | $782.84 | 2019-2025 | Acuvue |
| Biotissue Holdings INC. | $513.32 | 2020-2025 | |
| Glaukos Corporation | $359.07 | 2019-2025 | Photrexa Viscous and Photrexa |
| Kala Pharmaceuticals, INC. | $344.97 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $299.41 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $222.45 | 2019-2022 | |
| Shire North American Group INC | $179.37 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $124.34 | 2022 | |
| Bausch & Lomb Americas INC. | $94.69 | 2022-2023 | |
| Harrow Eye, LLC | $53.91 | 2024-2025 | Vevye |
| Optos, INC. | $37.63 | 2019 | |
| Abbvie INC. | $27.81 | 2022 | |
| Maculogix, INC. | $27.65 | 2019-2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $26.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.